Published in World J Urol on August 17, 2007
Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev (2009) 1.19
Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics (2012) 0.88
Osmoprotective proteome adjustments in mouse kidney papilla. Biochim Biophys Acta (2011) 0.82
Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients. J Cancer (2014) 0.81
Diagnostic Applications of Nuclear Magnetic Resonance-Based Urinary Metabolomics. Magn Reson Insights (2017) 0.76
Urinary Peptide patterns in native kidneys and kidney allografts. Transplantation (2009) 0.76
Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer (2012) 0.76
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
Intriguing Interaction of Bacteriophage-Host Association: An Understanding in the Era of Omics. Front Microbiol (2017) 0.75
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Fourier transform ion cyclotron resonance mass spectrometry: a primer. Mass Spectrom Rev (1998) 4.66
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (2004) 4.58
The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol (2006) 3.79
Protein identification using sequential ion/ion reactions and tandem mass spectrometry. Proc Natl Acad Sci U S A (2005) 3.77
Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst (2005) 3.31
Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int (2006) 3.00
Proteomics and cancer: running before we can walk? Nature (2004) 2.92
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Reactions of polypeptide ions with electrons in the gas phase. Mass Spectrom Rev (2003) 2.71
Discovery of urinary biomarkers. Mol Cell Proteomics (2006) 2.70
The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun (2002) 2.51
Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis (2000) 2.36
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol (2006) 2.29
Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int (2004) 1.95
Molecular classification of cancer types from microarray data using the combination of genetic algorithms and support vector machines. FEBS Lett (2003) 1.90
Precise and parallel characterization of coding polymorphisms, alternative splicing, and modifications in human proteins by mass spectrometry. Mol Cell Proteomics (2005) 1.86
Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Mol Cell Proteomics (2005) 1.71
Current developments in SELDI affinity technology. Mass Spectrom Rev (2003) 1.67
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int (2005) 1.63
Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis. Clin Chem (1979) 1.61
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.57
Top down mass spectrometry of < 60-kDa proteins from Methanosarcina acetivorans using quadrupole FRMS with automated octopole collisionally activated dissociation. Mol Cell Proteomics (2006) 1.57
Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem (2005) 1.50
Construction of a hybrid quadrupole/Fourier transform ion cyclotron resonance mass spectrometer for versatile MS/MS above 10 kDa. J Am Soc Mass Spectrom (2004) 1.46
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood (2007) 1.44
Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant (2005) 1.39
OMICS-driven biomarker discovery in nutrition and health. J Biotechnol (2006) 1.39
Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics (2006) 1.36
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis (2006) 1.33
Constancy of urinary creatinine excretion. J Lab Clin Med (1958) 1.29
Advancing proteomics with ion/ion chemistry. Biotechniques (2006) 1.29
Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int (2004) 1.29
MSight: an image analysis software for liquid chromatography-mass spectrometry. Proteomics (2005) 1.26
Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev (2005) 1.26
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis (2005) 1.24
Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis (2002) 1.22
Detection and localization of protein modifications by high resolution tandem mass spectrometry. Mass Spectrom Rev (2005) 1.22
Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol Pathol (2005) 1.15
Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun (2003) 1.13
Multidimensional protein identification technology (MudPIT): technical overview of a profiling method optimized for the comprehensive proteomic investigation of normal and diseased heart tissue. J Am Soc Mass Spectrom (2005) 1.13
Bio-support vector machines for computational proteomics. Bioinformatics (2004) 1.08
Human tissue profiling with multidimensional protein identification technology. J Proteome Res (2005) 1.07
The role of separation science in proteomics research. Electrophoresis (2001) 1.02
Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics (2005) 0.97
New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol (2006) 0.97
Serum proteomics in cancer diagnosis and management. Annu Rev Med (2004) 0.93
Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis (2001) 0.93
SELDI ProteinChip array in oncoproteomic research. Technol Cancer Res Treat (2002) 0.92
Proteomic approaches in the search for disease biomarkers. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.92
High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics (2006) 0.92
Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery. J Proteome Res (2006) 0.92
Proteomic analysis in the neurosciences. Mol Cell Proteomics (2002) 0.89
Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. Clin Chim Acta (2005) 0.88
Capillary electrophoresis-mass spectrometry: 15 years of developments and applications. Electrophoresis (2003) 0.88
Proteomic profiling of human urine using multi-dimensional protein identification technology. J Chromatogr A (2005) 0.88
Recent advances in the application of capillary electrophoresis with mass spectrometric detection. Electrophoresis (2006) 0.87
Advances in the analysis of proteins and peptides by capillary electrophoresis with matrix-assisted laser desorption/ionization and electrospray-mass spectrometry detection. Electrophoresis (2005) 0.86
A matrix-assisted laser desorption/ionization mass spectrometry study of the non-enzymatic glycation products of human globins in diabetes. Rapid Commun Mass Spectrom (2005) 0.84
Urine profiling using capillary electrophoresis-mass spectrometry and multivariate data analysis. J Chromatogr A (2006) 0.83
A robust approach for the analysis of peptides in the low femtomole range by capillary electrophoresis-tandem mass spectrometry. Electrophoresis (2002) 0.83
Functional proteomics; current achievements. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.82
Tagless extraction-retentate chromatography: a new global protein digestion strategy for monitoring differential protein expression. Electrophoresis (2002) 0.81
Capillary electrophoresis - mass spectrometry: survey on developments and applications 2003-2004. Electrophoresis (2005) 0.81
Exploiting natural peptide diversity: novel research tools and drug leads. Curr Opin Biotechnol (2004) 0.80
Searching for biomarkers of heart failure in the mass spectra of blood plasma. Proteomics (2006) 0.80
A rapid method to capture and screen for transcription factors by SELDI mass spectrometry. Biochem Biophys Res Commun (2002) 0.79
On-line capillary electrophoresis-mass spectrometry for the analysis of biomolecules. Electrophoresis (2004) 0.79
Label-free semiquantitative peptide feature profiling of human breast cancer and breast disease sera via two-dimensional liquid chromatography-mass spectrometry. Mol Cell Proteomics (2006) 0.78
The use of knowledge-based systems to improve medical knowledge about urine analysis. Clin Chim Acta (2000) 0.78
Interfaces for coupled liquid-phase separation/mass spectrometry techniques. An update on recent developments. J Mass Spectrom (2002) 0.77
An automated, sheathless capillary electrophoresis-mass spectrometry platform for discovery of biomarkers in human serum. Electrophoresis (2005) 0.77
Clinical proteomics: a question of technology. Rapid Commun Mass Spectrom (2004) 0.76
Monomer surface modifications for rapid peptide analysis by capillary electrophoresis and capillary electrochromatography coupled to electrospray ionization-mass spectrometry. Electrophoresis (2004) 0.75
Artificial neural network technologies to identify biomarkers for therapeutic intervention. Curr Opin Mol Ther (2004) 0.75
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol (2006) 2.29
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Urine in clinical proteomics. Mol Cell Proteomics (2008) 2.05
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. Cell (2004) 1.79
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65
Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol (2002) 1.63
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int (2005) 1.63
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.57
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res (2009) 1.56
Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res (2007) 1.52
Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med (2006) 1.52
Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol (2010) 1.48
Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics (2007) 1.47
Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circ Cardiovasc Genet (2014) 1.44
Urinary proteome analysis to exclude severe vesicoureteral reflux. Pediatrics (2012) 1.42
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes (2003) 1.39
Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes (2012) 1.38
Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood (2004) 1.33
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis (2006) 1.33
Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int (2004) 1.29
Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology (2011) 1.28
Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev (2005) 1.26
Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis (2007) 1.26
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis (2005) 1.24
Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant (2005) 1.24
Urinary proteomics for prediction of preeclampsia. Hypertension (2011) 1.20
Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway. J Biol Chem (2002) 1.17
Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics (2010) 1.16
Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A (2003) 1.16
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int (2005) 1.13
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int (2009) 1.12
Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis (2005) 1.12
Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications (2005) 1.12
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One (2010) 1.12
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut (2012) 1.11
The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics (2009) 1.11
Protein kinase C delta induces Src kinase activity via activation of the protein tyrosine phosphatase PTP alpha. J Biol Chem (2003) 1.11
Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int (2010) 1.10
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens (2010) 1.09
Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther (2009) 1.08
Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One (2011) 1.07
Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.06
Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res (2009) 1.05
A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol (2003) 1.03
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res (2009) 1.02
Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. Clin J Am Soc Nephrol (2013) 1.02
The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl (2008) 1.01
Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl (2008) 1.00
Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl (2011) 0.99
Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant (2009) 0.98
Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant (2004) 0.98
The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) (2005) 0.95
Induction of apoptosis by protein kinase C delta is independent of its kinase activity. J Biol Chem (2002) 0.93
High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics (2006) 0.92
The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal (2009) 0.92
Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J (2012) 0.91
A peptidomic approach to biomarker discovery for bovine mastitis. J Proteomics (2013) 0.91
Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics (2013) 0.91
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. Br J Pharmacol (2009) 0.90
A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Syst Biol (2013) 0.90
Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice. PLoS One (2013) 0.90
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem (2005) 0.90
Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy. Contrib Nephrol (2008) 0.90
Establishment of a European Network for Urine and Kidney Proteomics. J Proteomics (2008) 0.89
Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One (2010) 0.89
Review on uraemic solutes II--variability in reported concentrations: causes and consequences. Nephrol Dial Transplant (2007) 0.89
A novel cross-talk in diacylglycerol signaling: the Rac-GAP beta2-chimaerin is negatively regulated by protein kinase Cdelta-mediated phosphorylation. J Biol Chem (2010) 0.89
Clinical proteomics in obstetrics and neonatology. Expert Rev Proteomics (2014) 0.88
CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One (2013) 0.88
Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics (2012) 0.88
Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics (2006) 0.88
Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis (2013) 0.88
Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV). Sci Transl Med (2013) 0.87
The V5 domain of protein kinase C plays a critical role in determining the isoform-specific localization, translocation, and biological function of protein kinase C-delta and -epsilon. Mol Cancer Res (2004) 0.87
Capillary electrophoresis-mass spectrometry in urinary proteome analysis: current applications and future developments. Anal Bioanal Chem (2008) 0.87
Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol (2009) 0.87
Urinary proteomics to support diagnosis of stroke. PLoS One (2012) 0.86
Identification and analysis of phosphopeptides. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.85
Value of proteomics applied to the follow-up in stem cell transplantation. Ann Hematol (2006) 0.85
Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. Expert Rev Proteomics (2014) 0.85
Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One (2012) 0.85
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol (2010) 0.85
Peptidomic analysis of rat urine using capillary electrophoresis coupled to mass spectrometry. Proteomics Clin Appl (2007) 0.85
Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol (2014) 0.85
Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis (2004) 0.84
Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis. Pancreas (2016) 0.84
Clinical application of urinary proteomics/peptidomics. Expert Rev Proteomics (2011) 0.84
Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes. Electrophoresis (2005) 0.84
Grand rounds in proteomics at the FDA white oak, silver spring, MD, USA, april 3, 2007. Proteomics Clin Appl (2007) 0.83
CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl (2015) 0.83
Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol (2015) 0.83
Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS One (2012) 0.82
The role of EUTox in uremic toxin research. Semin Dial (2009) 0.82
Capillary electrophoresis coupled to mass spectrometry for biomarker discovery and diagnosis of kidney diseases. Contrib Nephrol (2008) 0.82